<?xml version='1.0' encoding='utf-8'?>
<document id="27128216"><sentence text="Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus."><entity charOffset="47-57" id="DDI-PubMed.27128216.s1.e0" text="ranolazine" /><entity charOffset="62-71" id="DDI-PubMed.27128216.s1.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.27128216.s1.e0" e2="DDI-PubMed.27128216.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27128216.s1.e0" e2="DDI-PubMed.27128216.s1.e1" /></sentence><sentence text="Ranolazine and metformin may be frequently co-administered in subjects with chronic angina and co-morbid type 2 diabetes mellitus (T2DM)"><entity charOffset="0-10" id="DDI-PubMed.27128216.s2.e0" text="Ranolazine" /><entity charOffset="15-24" id="DDI-PubMed.27128216.s2.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.27128216.s2.e0" e2="DDI-PubMed.27128216.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27128216.s2.e0" e2="DDI-PubMed.27128216.s2.e1" /></sentence><sentence text=" The potential for a drug-drug interaction was explored in two phase 1 clinical studies in subjects with T2DM to evaluate the pharmacokinetics and safety of metformin 1000 mg BID when administered with ranolazine 1000 mg BID (Study 1, N = 28) or ranolazine 500 mg BID (Study 2, N = 25) as compared to metformin alone"><entity charOffset="157-166" id="DDI-PubMed.27128216.s3.e0" text="metformin" /><entity charOffset="202-212" id="DDI-PubMed.27128216.s3.e1" text="ranolazine" /><entity charOffset="246-256" id="DDI-PubMed.27128216.s3.e2" text="ranolazine" /><entity charOffset="301-310" id="DDI-PubMed.27128216.s3.e3" text="metformin" /><pair ddi="false" e1="DDI-PubMed.27128216.s3.e0" e2="DDI-PubMed.27128216.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27128216.s3.e0" e2="DDI-PubMed.27128216.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27128216.s3.e0" e2="DDI-PubMed.27128216.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27128216.s3.e0" e2="DDI-PubMed.27128216.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27128216.s3.e1" e2="DDI-PubMed.27128216.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27128216.s3.e1" e2="DDI-PubMed.27128216.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27128216.s3.e1" e2="DDI-PubMed.27128216.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27128216.s3.e2" e2="DDI-PubMed.27128216.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27128216.s3.e2" e2="DDI-PubMed.27128216.s3.e3" /></sentence><sentence text=" Co-administration of ranolazine 1000 mg BID with metformin 1000 mg BID resulted in 1"><entity charOffset="22-32" id="DDI-PubMed.27128216.s4.e0" text="ranolazine" /><entity charOffset="50-59" id="DDI-PubMed.27128216.s4.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.27128216.s4.e0" e2="DDI-PubMed.27128216.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27128216.s4.e0" e2="DDI-PubMed.27128216.s4.e1" /></sentence><sentence text="53- and 1" /><sentence text="79-fold increases in steady-state metformin Cmax and AUCtau , respectively; co-administration of ranolazine 500 mg BID with metformin 1000 mg BID resulted in 1"><entity charOffset="34-43" id="DDI-PubMed.27128216.s6.e0" text="metformin" /><entity charOffset="97-107" id="DDI-PubMed.27128216.s6.e1" text="ranolazine" /><entity charOffset="124-133" id="DDI-PubMed.27128216.s6.e2" text="metformin" /><pair ddi="false" e1="DDI-PubMed.27128216.s6.e0" e2="DDI-PubMed.27128216.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27128216.s6.e0" e2="DDI-PubMed.27128216.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27128216.s6.e0" e2="DDI-PubMed.27128216.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27128216.s6.e1" e2="DDI-PubMed.27128216.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27128216.s6.e1" e2="DDI-PubMed.27128216.s6.e2" /></sentence><sentence text="22- and 1" /><sentence text="37-fold increases in steady-state metformin Cmax and AUCtau , respectively"><entity charOffset="34-43" id="DDI-PubMed.27128216.s8.e0" text="metformin" /></sentence><sentence text=" Co-administration of ranolazine and metformin was well tolerated in these T2DM subjects, with no serious adverse events or drug-related adverse events leading to discontinuation"><entity charOffset="22-32" id="DDI-PubMed.27128216.s9.e0" text="ranolazine" /><entity charOffset="37-46" id="DDI-PubMed.27128216.s9.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.27128216.s9.e0" e2="DDI-PubMed.27128216.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27128216.s9.e0" e2="DDI-PubMed.27128216.s9.e1" /></sentence><sentence text=" The most common adverse events were nausea, diarrhea, and dizziness" /><sentence text=" These findings are consistent with a dose-related interaction between ranolazine and metformin, and suggest that a dose adjustment of metformin may not be required with ranolazine 500 mg BID; whereas, the metformin dose should not exceed 1700 mg of total daily dose when using ranolazine 1000 mg BID"><entity charOffset="71-81" id="DDI-PubMed.27128216.s11.e0" text="ranolazine" /><entity charOffset="86-95" id="DDI-PubMed.27128216.s11.e1" text="metformin" /><entity charOffset="135-144" id="DDI-PubMed.27128216.s11.e2" text="metformin" /><entity charOffset="170-180" id="DDI-PubMed.27128216.s11.e3" text="ranolazine" /><entity charOffset="206-215" id="DDI-PubMed.27128216.s11.e4" text="metformin" /><entity charOffset="278-288" id="DDI-PubMed.27128216.s11.e5" text="ranolazine" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e0" e2="DDI-PubMed.27128216.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e0" e2="DDI-PubMed.27128216.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e0" e2="DDI-PubMed.27128216.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e0" e2="DDI-PubMed.27128216.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e0" e2="DDI-PubMed.27128216.s11.e4" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e0" e2="DDI-PubMed.27128216.s11.e5" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e1" e2="DDI-PubMed.27128216.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e1" e2="DDI-PubMed.27128216.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e1" e2="DDI-PubMed.27128216.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e1" e2="DDI-PubMed.27128216.s11.e4" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e1" e2="DDI-PubMed.27128216.s11.e5" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e2" e2="DDI-PubMed.27128216.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e2" e2="DDI-PubMed.27128216.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e2" e2="DDI-PubMed.27128216.s11.e4" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e2" e2="DDI-PubMed.27128216.s11.e5" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e3" e2="DDI-PubMed.27128216.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e3" e2="DDI-PubMed.27128216.s11.e4" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e3" e2="DDI-PubMed.27128216.s11.e5" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e4" e2="DDI-PubMed.27128216.s11.e4" /><pair ddi="false" e1="DDI-PubMed.27128216.s11.e4" e2="DDI-PubMed.27128216.s11.e5" /></sentence><sentence text="" /></document>